Target Information

Target General Infomation
Target ID
T50444
Former ID
TTDC00213
Target Name
Connective tissue growth factor
Gene Name
CTGF
Synonyms
CCN2; Hypertrophic chondrocyte-specific protein 24; Long; CTGF
Target Type
Clinical Trial
Disease Diabetic nephropathy [ICD9: 250.4; ICD10: E11.21]
Fibrosis [ICD9: 709.2; ICD10: L90.5]
Type 2 diabetes; Idiopathic pulmonary fibrosis [ICD9: 250, 250.00, 250.02, 515, 516.3, 709.2; ICD10: E08-E13, E11, J84.1, L90.5]
Function
Major connective tissue mitoattractant secreted by vascular endothelial cells. Promotes proliferation and differentiation of chondrocytes. Mediates heparin- and divalent cation-dependent cell adhesion in many cell types including fibroblasts, myofibroblasts, endothelial and epithelial cells. Enhances fibroblast growth factor-induced DNA synthesis.
BioChemical Class
CCN intercellular signaling protein
Target Validation
T50444
UniProt ID
P29279
Sequence
MTAASMGPVRVAFVVLLALCSRPAVGQNCSGPCRCPDEPAPRCPAGVSLVLDGCGCCRVC
AKQLGELCTERDPCDPHKGLFCHFGSPANRKIGVCTAKDGAPCIFGGTVYRSGESFQSSC
KYQCTCLDGAVGCMPLCSMDVRLPSPDCPFPRRVKLPGKCCEEWVCDEPKDQTVVGPALA
AYRLEDTFGPDPTMIRANCLVQTTEWSACSKTCGMGISTRVTNDNASCRLEKQSRLCMVR
PCEADLEENIKKGKKCIRTPKISKPIKFELSGCTSMKTYRAKFCGVCTDGRCCTPHRTTT
LPVEFKCPDGEVMKKNMMFIKTCACHYNCPGDNDIFESLYYRKMYGDMA
Drugs and Mode of Action
Drug(s) FG-3019 Drug Info Phase 2 Type 2 diabetes; Idiopathic pulmonary fibrosis [536836]
RXI-109 Drug Info Phase 2 Fibrosis [524924]
FG-3019 Drug Info Phase 1b Diabetic nephropathy [536836]
Inhibitor FG-3019 Drug Info [536528]
Target Expression Profile (TEP) and Drug Resistance Mutation (DRM)
TEP EXP Info
Pathways
KEGG Pathway Hippo signaling pathway
NetPath Pathway TGF_beta_Receptor Signaling Pathway
Pathway Interaction Database amb2 Integrin signaling
TGF-beta receptor signaling
Reactome PPARA activates gene expression
YAP1- and WWTR1 (TAZ)-stimulated gene expression
WikiPathways Cytodifferentiation (Part 3 of 3)
Induction (Part 1 of 3)
Regulation of Lipid Metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
YAP1- and WWTR1 (TAZ)-stimulated gene expression
References
Ref 524924ClinicalTrials.gov (NCT02246465) A Study to Evaluate the Effectiveness and Safety of RXI 109 on the Outcome of Revised Hypertrophic Scars. U.S. National Institutes of Health.
Ref 536836Agents in development for the treatment of diabetic nephropathy. Expert Opin Emerg Drugs. 2008 Sep;13(3):447-63.
Ref 536528Current and emerging drugs for idiopathic pulmonary fibrosis. Expert Opin Emerg Drugs. 2007 Nov;12(4):627-46.
Ref 544379Cyr61/CTGF/Nov family proteins in gastric carcinogenesis. World J Gastroenterol. 2014 February 21; 20(7): 1694-1700.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.